Earnings History Data for Chemomab Therapeutics Ltd. (CMMB) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Chemomab Therapeutics Ltd.
Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 07-03-2024 | PM | CMMB | Chemomab Therapeutics Ltd. | 7.15 | -0.26 | -0.40 | -0.72 | Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.01 [3/7/2024 7:55 AM] |
0.7980 | 0.09 (12.35%) |
0.71 | 0.0 (0.17%) |
0.42 - 1.89 | 266,720 | 130,000 | 16,503 | ||
| 09-11-2023 | PM | CMMB | Chemomab Therapeutics Ltd. | 7.24 | -0.34 | -0.60 | -0.70 | Chemomab Therapeutics GAAP EPS of $0.017 [11/9/2023 10:39 AM] |
0.56 | -0.08 (-12.36%) |
0.67 | 0.03 (4.99%) |
0.50 - 5.35 | 33,654 | 20,000 | 368 | ||
| 11-05-2023 | PM | 6:00 AM ET (May 11) |
CMMB | Chemomab Therapeutics Ltd. | 17.46 | -0.80 | -0.80 | -0.44 | Chemomab Therapeutics - ADR GAAP EPS of -$0.04 in-line [5/11/2023 11:44 AM] |
1.61 | -0.03 (-1.83%) |
1.64 | 0.0 (0.00%) |
1.38 - 5.35 | 9,413 | 20,000 | 2,095 | |
| 11-11-2022 | PM | 6:00 AM ET (Nov 11) |
CMMB | Chemomab Therapeutics Ltd. | 24.01 | -0.70 | -0.60 | -0.26 | Chemomab Therapeutics - ADR GAAP EPS of -$0.04 beats by $0.19 [11/11/2022 6:06 AM] |
2.06 | -0.02 (-0.96%) |
2.29 | 0.21 (10.10%) |
1.75 - 10.70 | 196,449 | 20,000 | 158,698 | |
| 12-08-2022 | PM | 6:00 AM ET (Aug 12) |
CMMB | Chemomab Therapeutics Ltd. | 36.95 | -0.54 | -0.60 | -0.26 | Chemomab Therapeutics - ADR GAAP EPS of -$0.027 [8/12/2022 6:14 AM] |
3.98 | 0.25 (6.70%) |
3.94 | 0.21 (5.63%) |
2.53 - 17.39 | 73,867 | 60,000 | 5,736 | |
|
||||||||||||||||||
| 12-05-2022 | PM | 6:00 AM ET (May 12) |
CMMB | Chemomab Therapeutics Ltd. | 32.62 | -0.44 | -0.40 | -0.22 | Chemomab Therapeutics - ADR GAAP EPS of -$0.022 [5/12/2022 6:25 AM] |
2.58 | -0.02 (-0.96%) |
0.0 | 0.0 (0.00%) |
2.53 - 27.92 | 21,796 | 30,000 | 0 | |
| 09-03-2022 | PM | 7:00 AM ET (Mar 9) |
CMMB | Chemomab Therapeutics Ltd. | 40.26 | -0.44 | -0.40 | 4.00 | Chemomab Therapeutics GAAP EPS of -$0.02 beats by $0.12 [3/9/2022 6:03 AM] |
3.93 | 0.30 (8.26%) |
4.00 | 0.37 (10.19%) |
3.25 - 131.20 | 66,242 | 80,000 | 14,551 | |
| 12-11-2021 | PM | CMMB | Chemomab Therapeutics | 108.00 | -0.26 | -0.02 | 0.00 | Chemomab Therapeutics - ADR EPS beats by $0.01 [11/12/2021 8:54 AM] |
9.82 | 0.38 (4.03%) |
9.77 | 0.33 (3.50%) |
8.46 - 168.80 | 103,208 | 290,000 | 923 | ||
| 13-05-2021 | PM | CMMB | Chemomab Therapeutics Ltd. | 192.35 | -0.22 | -0.43 | -6.56 | Chemomab Therapeutics - ADR reports Q1 results [5/13/2021 9:32 AM] |
16.59 | -0.57 (-3.32%) |
17.55 | 0.39 (2.27%) |
12.32 - 168.80 | 107,525 | 220,000 | 1,786 | ||